- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Tailoring Care in ITP Through a Health Equity Lens
A panelist discusses how personalized ITP care requires open conversations about testing costs, insurance coverage, and treatment accessibility, with clinicians helping patients navigate financial barriers through pharmaceutical assistance programs and clinical trials.
EP: 1.Understanding Immune Thrombocytopenia: Pathophysiology, Classification, and Differentiation
EP: 2.Diagnostic and Patient Education Strategies in ITP
EP: 3.Managing Bleeding Risk in Patients with ITP
EP: 4.Living with ITP: Impact of Fatigue and Other Symptoms on Patients’ Quality of Life
EP: 5.Tailoring Care in ITP Through a Health Equity Lens
EP: 6.Looking Ahead in ITP: Addressing Unmet Needs and Embracing Innovation
EP: 7.Key Clinical Signs and Symptoms Used in Diagnosis of Immune Thrombocytopenia
EP: 8.Clinical Decision-Making in ITP: Timing Treatment Initiation and Therapy Goals
EP: 9.Current Treatment Algorithm for Management of Immune Thrombocytopenia
EP: 10.Addressing the Limitations of Current ITP Therapies
Personalized care for ITP patients must consider financial barriers, as diagnostic testing can be expensive. Healthcare providers should maintain open communication regarding which tests are essential for confident diagnosis, which may not be covered by insurance, and what alternatives exist for patients with limited or no coverage.
Physicians should discuss all available treatment options honestly while considering accessibility factors. Support mechanisms include assistance from the clinical office, ITP support organizations, pharmaceutical company programs, and clinical trials that may cover both diagnostic and therapeutic interventions when traditional options are financially out of reach.
While discussing financial aspects of care isn't comfortable for many physicians, the current healthcare climate demands understanding potential barriers to access. Open dialogue about testing costs, copay concerns, and payment responsibilities allows healthcare teams to help patients navigate these challenges and receive appropriate care for their condition.
Immune Checkpoint Inhibitors More Effective vs Bevacizumab in Nonsquamous NSCLC
August 6th 2025Bevacizumab combined with chemotherapy was not as effective in advanced driver gene-negative nonsquamous non–small cell lung cancer (NSCLC) compared with immune checkpoint inhibitors plus chemotherapy.
Read More
Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds
August 5th 2025Researchers discovered a significant negative correlation between an individual's oxidative balance score and systemic immune-inflammation index, highlighting the role of antioxidants in reducing inflammation.
Read More
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discussed innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
